The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2023 | Updates on the diagnosis, risk stratification and treatment of lower-risk MDS
In this discussion, Sanam Loghavi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Rami Komrokji, MD, Moffitt Cancer Center, Tampa, FL, discuss advances made in the diagnosis, risk stratification and treatment of lower-risk myelodysplastic syndromes (LR-MDS), highlighting findings from recent clinical trials. This discussion took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023), held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
